The smart PV module market is expected to exceed 4GW in 2020

Abstract According to the latest analysis released by IHSMarkit in the UK, the business model of solar photovoltaic micro-inverters and power optimizer suppliers will be transformed from independent units to integrated systems, such as intelligent communication modules. IHS Technology Photovoltaic Micro Inverter and Power Optimizer...
According to the latest analysis released by IHS Markit in the UK, the business model of solar PV micro-inverters and power optimizer suppliers will be transformed from a stand-alone unit to an integrated system, such as an intelligent communication module.
The IHS Technology Photovoltaic Micro Inverter and Power Optimizer Report predicts that revenue from smart communication components will rise from $100 million in 2015 to nearly $500 million in 2020.
Corres Gilligan, IHS Technology Research Manager, said: "Suppliers are shifting their business model from selling independent products to selling off-the-shelf integrated models. It will help capture emerging markets, increase sales channel efficiency and reduce customer costs."
The IHS technical report predicts that micro-inverters and power optimizers will increasingly be installed in factories in the form of AC and smart components.
Global Trends and Drivers The United States is the largest market for micro-inverters and power optimizers, but Asian and European markets such as China, Japan, Australia, Germany, France and the Netherlands are expected to face strong demand in the next five years.
IHS Technology predicts that in 2015, the smart communication component market will be less than 200MW, and by 2020 it will grow by more than 4GW, and integrated products will be favored in the global market.

Description about Coronavirus(COVID-19)test Test

The Coronavirus(COVID-19)test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 novel coronavirus in human whole blood, serum or plasma. The Coronavirus(COVID-19)test is intended for professionals within highly complex settings and or pharmacies. The test delivers rapid results between 2 and 10 minutes from individuals having signs and symptoms of SARS-CoV-2 infection


What conditions to do the Coronavirus(COVID-19)test?

1.Breating difficulty

2.skin sores, which may become a skin ulcer that heals very slowly

3.stuffy nose, runny nose, and nosebledds.

4.swallowing difficulty


TEST OVERVIEW for the Coronavirus(COVID-19)test

  • Utilizes human whole blood, serum, or plasma
  • Used in rapid, qualitative and differential detection of IgG and IgM antibodies
  • Delivers clinical results between 2 and 10 minutes at the point-of-care
  • Visual interpretation of results
  • No special equipment needed

PERFORMANCE CHARACTERISTICS

The COVID-19 lgG/lgM Rapid Test (Whole Blood/Serum/Plasma) has been evaluated with the 126 samples obtained from patients exhibiting pneumonia or respiratory symptoms. The results were compared to Fluorescent Real Time Polymerase Chain Reaction (RT-PCR) or clinical diagnosis (including chest Computed Tomography and clinical signs etc.) of [Diagnosis and treatment of novel coronavirus pneumonia."

IgG/IgM Rapid Test results compared to SARS-CoV-2 RT-PCR results:

COVID-19 RT-PCR Assay Coronavirus(COVID-19)test
Positive Negative Total
Positive 103 9 112
Negative 0 14 14
Total 103 23 126
95% CI
Sensitivity 103/112 91.9% (85.3% – 96.3%)
Specificity 14/14 100% (76.8% – 100%)
Overall 117/126 92.8% (86.9% – 96.7%)

The sensitivity of lgM only test is 89.2% (100/112) and specificity is 100% (14/14).
The sensitivity of lgG & IgM test is 91.9% (103/112) and specificity is 100% (14/14).

RT-PCR Method testing was included as clinical site method. Nucleic acid was detected by probe fluorescence PCR. This product contained primers and probes (ORF1ab gene and N gene strains of coronavirus) and internal controls (housekeeping gene beta Globin gene sequences) used in RT-PCR for the in vitro qualitative detection of SARS-CoV-2 RNA in nasopharyngeal swab specimens. The novel coronavirus2019-ncov specific probe was respectively labeled with FAM fluorescence and ROX fluorescence, and the internal standard gene was labeled with VIC fluorescence. The minimum detection limit of the fluorescent RT-PCR assay is 10 copies/reaction.

LIMITATIONS

  1. Use fresh samples only.
  2. This test has not been reviewed by the FDA.
  3. Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus.
  4. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
  5. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
  6. Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E. Some specimens containing unusually high titer of heterophile antibodies or rheumatoid factor may affect expected results.
  7. Not for the screening of donated bloodCorona Test 3

Coronavirus(COVID-19)test

Rapid Test,Coronavirus Test Kit,Coronavirus Test,Covid-19 Test

Dongguan Smart Furniture Co.,Ltd , https://www.smtfurniture.com